Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
In 2014, Amgen sued Sanofi and Regeneron to claim ownership of an entire class of cholesterol drugs. Nine years later, the Supreme Court ruled against them - but they won where it mattered most.
Read the full articleYou might also wanna read
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
FDA Approves First PCSK9 Inhibitor Pill for Cholesterol
(MedPage Today) -- The FDA approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for lowering cholesterol. Enlicitide is now app
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop
FDA approves Merck's Lipfendra, first daily PCSK9 inhibitor pill for high cholesterol
Merck said on Thursday the Food and Drug Administration has approved Lipfendra, a PCSK9 inhibitor cholesterol pill.
nbcnews.to·9h agoFDA approves Merck's Lipfendra, first daily PCSK9 inhibitor pill for high cholesterol
Merck said on Thursday the Food and Drug Administration has approved Lipfendra, a PCSK9 inhibitor cholesterol pill.
nbcnews.to·9h agoBiogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ru
Comments
Sign in to join the conversation.
No comments yet. Be the first.